By Colin Kellaher


Targovax ASA Tuesday said the U.S. Food and Drug Administration granted fast-track designation to ONCOS-102, the company's lead clinical candidate, in PD-1-refractory advanced melanoma.

The Lysaker, Norway, clinical-stage immune-oncology company said the designation is based on its current pre-clinical and clinical data package, including mechanistic evidence showing an association between ONCOS-102-induced immune activation and tumor responses.

The FDA's fast-track program is designed to facilitate the development and expedite the review of treatments for serious or potentially life-threatening illnesses with high unmet medical needs.

Targovax previously received fast-track designation for ONCOS-102 in malignant pleural mesothelioma.

Targovax shares rose nearly 6% Tuesday to NOK8.99.


Write to Colin Kellaher at


(END) Dow Jones Newswires

June 22, 2021 09:07 ET (13:07 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.